464 results on '"Chambost H"'
Search Results
2. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
3. Bleeding phenotype according to factor level in 825 children with non-severe hemophilia; data from the PedNet cohort
4. Accompagnement en onco-hématologie pédiatrique : mise en place de plans pharmaceutiques personnalisés pour les enfants traités par anticancéreux oraux
5. PB1249 Prospective, Observational Study of the Clinical Characteristics of Adults and Adolescents with Severe Hemophilia A
6. PB0650 Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Pediatric Patients with Hemophilia B: A Review of Results from Phase 3 Trial Studies
7. OC 20.1 Bleeding, FVIII Activity, and Safety 3 Years After Gene Transfer with Valoctocogene roxaparvovec: Results from GENEr8-1
8. OC 43.1 A Survey on Clinical Praxis in Initiating Emicizumab Prophylaxis in Previously Untreated Patients in the PedNet Centers
9. PB0638 Final Data from A-MOVE: 12-Month Prospective Multicentre Study to Investigate the Impact of Systematic Joint Examination on Treatment Management Decisions in Patients with Hemophilia A in France
10. Mise au point : diagnostic d’hyperéosinophilie chez l’enfant
11. Dispositif pluridisciplinaire d’accompagnement des enfants et de leur famille depuis l’annonce diagnostique d’une forme sévère d’hémophilie
12. Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis
13. Actualité sur le risque de survenue d’inhibiteur à l’initiation du traitement par concentré de facteur VIII dans l’hémophilie A sévère
14. Transfusion plaquettaire et iso-immunisation anti-Rh1 : intérêt de la séroprévention
15. Hémorragie intracrânienne compliquant un purpura thrombopénique immunologique aigu de l’enfant : une étude rétrospective nationale
16. Le programme L.E.A., suivi prolongé après traitement d’une leucémie aiguë de l’enfance : structuration, résultats et perspectives
17. Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study
18. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
19. Full but impaired activation of innate immunity effectors and virus-specific T cells during CMV and EBV disease following cord blood transplantation
20. Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study
21. Hémophilie et pathologies cardiovasculaires
22. Le facteur VII recombinant activé en pédiatrie. Hémostatique universel ?
23. Efficacy, pharmacokinetics (PK) and safety results of a phase 3 clinical study of recombinant fusion protein linking coagulation factor IX with albumin (RIX-FP) in previously treated children with hemophilia B: OR346
24. Plasma-derived factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A: report of the FranceCoag Network: OR143
25. In haemophilic patients tfpi levels influence thrombin generation profile and TFPI neutralization normalizes thrombin generation potential: OR012
26. Purpura thrombocytopénique auto-immun : à propos d’une cohorte prospective de 147 enfants pris en charge dans le réseau d’hématologie pédiatrique des régions PACA et Corse (RHémaP)
27. Interim results from the prospective observational study on Novoseven® room temperature stable (VII25) in patients with hemophilia A or B: PCI09
28. Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI
29. Health status and quality of life in long-term survivors of childhood leukaemia: the impact of haematopoietic stem cell transplantation
30. CD34+ progenitors are reproducibly recovered in thawed umbilical grafts, and positively influence haematopoietic reconstitution after transplantation
31. Long-term follow-up of neonatal intracranial haemorrhage in children with severe haemophilia
32. Treatment of girls and women with haemophilia A and haemophilia B: a retrospective study in the francecoag cohort
33. Cancer detection and management in patients with haemophilia: a retrospective European multicentre study
34. Clinical evidence implicating gamma-delta T cells in EBV control following cord blood transplantation
35. Impact of haemophilia on cancer detection and management: a retrospective study: PB 4.60–6
36. ORTHem 15–25: French retrospective national survey of different treatment regimens in patients with severe (factor VIII or IX = 2%) haemophilia A and B between 15 and 25 years old: PB 4.36–5
37. Alloimmune thrombocytopenia masking a bernard soulier syndrome in a congenital nephrotic syndrome of the Finnish type (nphs1): PB 4.29–3
38. Long-lasting recombinant factor FIX Fc fusion (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study: PA 2.07–4
39. Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry
40. A prospective study of Epstein–Barr virus load in 85 hematopoietic stem cell transplants
41. Enjeux d'une prise en charge pédiatrique précoce de l'hémophilie sévère
42. Impact of Choice of Treatment for Bleeding Episodes on Inhibitor Outcome in Patients With Mild/Moderate Hemophilia A and Inhibitors
43. Fine characterization of childhood and adult acute lymphoblastic leukemia (ALL) by a proB and preB surrogate light chain-specific mAb and a proposal for a new B cell ALL classification
44. Acute myeloid leukaemia triggering via CD40 induces leukocyte chemoattraction and cytotoxicity against allogenic or autologous leukemic targets
45. Immune reconstitution and outcome after unrelated cord blood transplantation: a single paediatric institution experience
46. Perinatal practices in the context of hemophilia carrier: Expert opinion from an international pediatric panel: PO-TU-166
47. Implementation of national recommendations of early prophylaxis in boys with severe hemophilia: Results from the Pups cohort of “FranceCoag network”: PO-TU-156
48. Update data of the FranceCoag Network, the French National Registry for Congenital Bleeding Disorders: PO-MO-024
49. Age at the first bleeding could be a predictor of hemorrhagic phenotype in patients with severe hemophilia: FP-MO-04.4-2
50. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38− leukemic progenitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.